Genzyme in Sanofi's Control - Analyst Blog
April 05 2011 - 8:15AM
Zacks
Sanofi-Aventis (SNY) recently announced the
successful completion of its exchange offer for all outstanding
shares of common stock of Genzyme Corporation
(GENZ). With 224,528,469 shares of Genzyme being validly tendered,
Sanofi now holds about 84.6% of Genzyme common stock (77% on a
fully-diluted basis).
The remaining shareholders of Genzyme have time until April 7,
2011 (6:00 p.m., New York City time) to tender their shares.
Meanwhile, the contingent value rights (CVRs), which were a part of
the deal, started trading on NASDAQ under the ticker symbol
“GCVRZ”.
As a reminder, per the terms of the deal announced in Feb 2011,
Genzyme shareholders will receive $74 per share in cash (or $20.1
billion) in addition to a CVR for each share. The CVR will allow
each shareholder to receive additional payments related to Lemtrada
(alemtuzumab for multiple sclerosis) and the achievement of
specified production volumes in 2011 for Cerezymeand Fabrazyme.
Acquisition to Create New Source of Growth at
Sanofi
With this acquisition, Sanofi is looking to create a new source
of growth. Sanofi has a high exposure to generic risk on many of
its leading franchises. The company suffered a blow with the entry
of a generic version of its anti-coagulant Lovenox, which was a
major contributor to the top-line.
In addition to Lovenox, we see generic risk to other products as
well. In such a scenario, it is imperative for Sanofi to
successfully develop and launch new products in order to make up
for the loss of revenues once major products lose exclusivity and
start facing generic competition. The acquisition of Genzyme will
boost Sanofi’s revenues as well as its pipeline.
Sanofi will also get the chance to expand its presence in
biotechnology. At the time of announcing the acquisition, Sanofi
said that it expects the deal to be accretive to its business net
EPS in the first year after closing. By 2013, the company expects
the deal to be accretive by €0.75 – €1.00.
GENZYME-GENERAL (GENZ): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
Zacks Investment Research
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From Oct 2023 to Oct 2024